Pulmatrix (NASDAQ:PULM) Coverage Initiated by Analysts at StockNews.com

Investment analysts at StockNews.com started coverage on shares of Pulmatrix (NASDAQ:PULM) in a research report issued to clients and investors on Sunday. The firm set a “hold” rating on the biotechnology company’s stock.

Pulmatrix Trading Down 5.9 %

NASDAQ PULM opened at $7.20 on Friday. The stock has a market capitalization of $26.29 million, a price-to-earnings ratio of -2.73 and a beta of 1.52. The business’s 50 day moving average is $5.20 and its two-hundred day moving average is $3.17. Pulmatrix has a 12-month low of $1.55 and a 12-month high of $8.44.

Pulmatrix Company Profile

Pulmatrix, Inc, a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.